News

May 19, 2017

Cytokinetics Receives FDA Orphan Drug Designation for CK-2127107 for SMA

Cytokinetics Receives FDA Orphan Drug Designation for CK-2127107 for SMA

Cytokinetics, Inc. recently announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CK-2127107, a next-generation fast skeletal muscle activator, for the potential treatment of spinal muscular...

READ MORE   |  

Topics: Clinical Trials, Front Page News

May 16, 2017

Cure SMA Announces 2017 Family Friendly Poster Session Presenters

Cure SMA Announces 2017 Family Friendly Poster Session Presenters

We’ve recently seen significant advances in SMA research come to fruition, and with 17 drug programs in development, including five in clinical trials, we are invested to treating all ages, stages and types of SMA. With such great promise in the research landscape, we know that...

READ MORE   |  

Topics: Conference, Front Page News

May 15, 2017

Cure SMA Awards $140,000 Grant to Alberto Kornblihtt, PhD, Universidad de Buenos Aires, Argentina

Cure SMA Awards $140,000 Grant to Alberto Kornblihtt, PhD, Universidad de Buenos Aires, Argentina

Cure SMA and FAME (Families of SMA, Argentina) have awarded a $140,000 research grant to Alberto Kornblihtt, PhD, at the Universidad de Buenos Aires, Argentina, for his project, "Epigenetics in SMN2 E7 Alternative Splicing.”

Epigenetics refers to changes that affect how...

READ MORE   |  

Topics: Research, Front Page News

Items 1 - 3 of 345  12345678910Next

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software